Vastus lateralis myocutaneous flap for ischial skin wound following the treatment of epithelioid sarcoma using pazopanib

• Published in: Journal of wound care Vol. 29; no. 6; pp. 335 - 339
• Main Authors: Tsujii, Masaya, Matsumine, Akihiko, Nakamura, Tomoki, Satonaka, Haruhiko, Sudo, Akihiro
• Format: Journal Article
• Language: English
• Published: London MA Healthcare 02-06-2020; Mark Allen Group Ltd
• Subjects: Adult; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - therapeutic use; Buttocks; Cancer surgery; Combined Modality Therapy; Female; Humans; Inhibitor drugs; Magnetic Resonance Imaging; Myocutaneous Flap; Nursing; Practice; Pyrimidines - administration & dosage; Pyrimidines - therapeutic use; Quadriceps Muscle; Sarcoma; Sarcoma - diagnostic imaging; Sarcoma - therapy; Skin & tissue grafts; Sulfonamides - administration & dosage; Sulfonamides - therapeutic use; Surgery; Targeted cancer therapy; Treatment Outcome; Wound Healing; vastus lateralis myocutaneous flap; sarcoma; ischial skin ulcer; pazopanib; reconstructive surgery
• ISSN: 0969-0700; 2052-2916
• DOI: 10.12968/jowc.2020.29.6.335

Pazopanib, a targeted molecular drug, has been proposed as an effective treatment for soft tissue tumour and as a novel adjuvant therapy. There has been a paradoxical concern that wound healing could be inhibited by its anti-angiogenic properties, especially in reconstructive surgery. This paper reports on a 28-year-old woman who underwent flap surgery due to a skin and soft tissue injury after an effective treatment with pazopanib for refractory epithelioid sarcoma. The flap survived without any complication in off-periods of pazopanib for four weeks before and after the surgery, although it is only recommended that the washout periods of pazopanib commence at least seven days before scheduled surgery.